Valneva SE has announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has revoked the marketing authorization for its chikungunya vaccine, IXCHIQ. This decision follows a further benefit-risk assessment by the UK's Commission on Human Medicines (CHM) and is based on a review of existing safety data. Valneva stated that this revocation does not stem from any new safety concerns.
The revocation is significant for Valneva, as it reflects the ongoing challenges faced by the company in the competitive biological products sector. However, Valneva has indicated that the impact of this decision on its overall sales revenue will be minimal, as the company has not actively distributed IXCHIQ in the UK for several months due to low sales among travelers.
Founded in 2013, Valneva SE specializes in developing and commercializing vaccines for infectious diseases, with a focus on addressing unmet medical needs. The company is listed on both Nasdaq and Euronext Paris under the ticker symbols VALN and VLA, respectively. Its recent filings include several 6-K forms, with the latest one dated October 8, 2026, providing updates on its business activities.
According to the filing, Valneva believes that the benefit-risk profile of IXCHIQ remains favorable when used according to the approved indications and precautions. The company has also highlighted that the decision by the MHRA does not affect IXCHIQ's marketing authorizations in other territories, including the European Union, Canada, and Brazil, where the vaccine continues to be marketed.
Valneva's strategic focus will now shift towards expanding access to IXCHIQ in endemic regions where the risk of chikungunya virus infection is highest. The company has decided not to appeal the MHRA's decision, citing its immaterial financial and commercial impact.
Looking ahead, Valneva plans to continue monitoring the safety and efficacy of IXCHIQ in other markets, as it has already administered approximately 187,000 doses globally. The company remains committed to advancing its vaccine pipeline, which includes other candidates addressing significant public health threats.
Details were not available in the SEC filing regarding any upcoming filings or specific next steps following this announcement.